Antagonists of HMG1 for treating inflammatory conditions
View Patent ↗There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
1. A method for treating a cardiovascular condition characterized by activation of the inflammatory cytokine cascade, comprising administering an effective amount of an antibody that specifically binds an HMG1 protein or an antigenic fragment thereof, wherein said antibody inhibits HMG1-mediated activation of the inflammatory cytokine cascade.
2. The method of claim 1 , wherein said antibody is a polyclonal antibody.
3. The method of claim 1 , wherein said antibody is a monoclonal antibody.
4. The method of claim 1 , wherein said antibody is a chimeric antibody.
5. The method of claim 1 , wherein said antibody is a single chain antibody.
6. The method of claim 1 , wherein said antibody is a human antibody.
7. The method of claim 1 , wherein said antibody is a humanized antibody.
8. The method of claim 1 , wherein said antibody can bind to a peptide consisting of the amino acid sequence GKGDPKKPRGKMSSC (SEQ ID NO:4).
9. A method for treating a cardiovascular condition characterized by activation of the inflammatory cytokine cascade, comprising administering a pharmaceutical composition comprising an effective amount of an antibody that specifically binds an HMG1 protein or an antigenic fragment thereof, wherein said antibody inhibits HMG1-mediated activation of the inflammatory cytokine cascade.
10. A method for treating a cardiovascular condition characterized by activation of the inflammatory cytokine cascade, comprising administering an effective amount of an antibody fragment that specifically binds an HMG1 protein or an antigenic fragment thereof, wherein said antibody fragment inhibits HMG1-mediated activation of the inflammatory cytokine cascade.
11. The method of claim 10 , wherein said antibody fragment is an antibody fragment of a polyclonal antibody.
12. The method of claim 10 , wherein said antibody fragment is an antibody fragment of a mono clonal antibody.
13. The method of claim 10 , wherein said antibody fragment is an antibody fragment of a chimeric antibody.
14. The method of claim 10 , wherein said antibody fragment is an antibody fragment of a single chain antibody.
15. The method of claim 10 , wherein said antibody fragment is an antibody fragment of a human antibody.
16. The method of claim 10 , wherein said antibody fragment is an antibody fragment of a humanized antibody.
17. The method of claim 10 , wherein said antibody fragment is an Fab fragment.
18. The method of claim 10 , wherein said antibody fragment can bind to a peptide consisting of the amino acid sequence GKGDPKKPRGKMSSC (SEQ ID NO:4).
19. A method for treating a cardiovascular condition characterized by activation of the inflammatory cytokine cascade, comprising administering a pharmaceutical composition comprising an effective amount of an antibody fragment that specifically binds an HMG1 protein or an antigenic fragment thereof, wherein said antibody fragment inhibits HMG1-mediated activation of the inflammatory cytokine cascade.